Hernandez-Ilizaliturri Lab Publications

• Kamdar M, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18;399(10343):2294-2308. 
• Lama R, et al. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. Front Oncol. 2022 Aug 5; 12:933446. doi: 10.3389/fonc.2022.933446. PMID: 35992795; PMCID: PMC9389462. 
• Torka P, et al. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer. 2022 Apr 15;128(8):1595-1604. doi: 10.1002/cncr.34106. Epub 2022 Feb 14. PMID: 35157306; PMCID: PMC10086838. 
• Torka P, et al. Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma. EJHaem. 2020 Jul;1(1):122-132. doi: 10.1002/jha2.2. Epub 2020 Apr 9. PubMed PMID: 33073261; PubMed Central PMCID: PMC7566777.  
• Runckel K, et al. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv. 2018 Dec 11;2(23):3516-3525. doi: 10.1182/bloodadvances.2018018168. PMID: 30530779; PMCID: PMC6290104. 
•  Bhatti M, et al. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget. 2018 Apr 24;9(31):21820-21830. doi: 10.18632/oncotarget.25072. PMID: 29774105; PMCID: PMC5955151. 

Recent publications

AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas

• Publication: Leukemia & Lymphoma, June 2023
• Authors: Torka P, Russell T, Mavis C, Gu J, Ghione P, Barth M, Hernandez-Ilizaliturri FJ 
• Citation: Leuk Lymphoma. 2023 Jun;64(6):1175-1185.

PubMedFull text

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report

• Publication: Journal of the National Comprehensive Cancer Network, February 2023
• Authors: Przespolewski ER, Baron J, Kashef F, Fu K, Jani Sait SN, Hernandez-Ilizaliturri F, Thompson J
• Citation: J Natl Compr Canc Netw. 2023 Feb;21(2):102-107.

PubMedFull text

• Gerson JN, et al. Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma. Blood Adv. 2023 Oct 24:bloodadvances.2023010757. doi: 10.1182/bloodadvances.2023010757.  
• Lin LH, et al. Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Target Oncol. 2023 Sep;18(5):685-695. doi: 10.1007/s11523-023-00992-4. Epub 2023 Aug 26. PMID: 37632592. 
• Gulati S, et al. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. JAMA Oncol. 2023 Oct 1;9(10):1390-1400. doi: 10.1001/jamaoncol.2023.2934. PMID: 37589970; PMCID: PMC10436185. 
• Mato AR, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696. PMID: 37407001. 
• Wang ML, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. doi: 10.1200/JCO.23.00562. Epub 2023 May 16. PMID: 37192437; PMCID: PMC10461952. 
• Wang X, et al. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia. Leukemia. 2023 Jun;37(6):1324-1335. doi: 10.1038/s41375-023-01889-x. Epub 2023 Apr 8. PMID: 37031300; PMCID: PMC10244170. 
• Torka P, et al. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Cancer J. 2023 Jan 11;13(1):9. doi: 10.1038/s41408-022-00763-w. PMID: 36631449; PMCID: PMC9834208. 
• Abramson JS, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023 Apr 6;141(14):1675-1684. doi: 10.1182/blood.2022018730. PMID: 36542826.